BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
Bets on China Data, Differentiation Strategy
Executive Summary
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
You may also be interested in...
Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe
The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.
Growing Pains: Charting The Rapid Rise Of Chinese IO
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.